Centre extends ban on UK flights till 7 Jan, advises caution on New Year s eve; cases of new COVID-19 strain rise to 20 An expert panel met to consider the Emergency Use Authorisation (EUA) requests of Pfizer, Serum Institute of India (SII) and Bharat Biotech for their COVID-19 vaccine candidates. As per reports, the SEC said it will reconvene on 1 January. FP Staff December 31, 2020 00:00:54 IST Representational image. AFP
The Centre on Wednesday extended the temporary suspension of passenger flights between the United Kingdom and India till 7 January.
This, as 14 more UK returnees tested positive for the new strain of the coronavirus , taking the tally of such cases in the country to 20.
CDSCO to consider emergency use authorisation request of Pfizer, Serum, Bharat Biotech on Jan 1
The expert committee on COVID-19 analysed the additional data and information that it had asked from SII and Bharat Biotech earlier this month
BusinessToday.In | December 30, 2020 | Updated 22:39 IST
Photo Credit: Business Standard
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) met on Wednesday to deliberate upon the emergency use authorisations of the Oxford-Astrazeneca vaccine, as applied by the Serum Institute of India (SII). The committee also considered the applications of Bharat Biotwech s Covaxin, and is to reconvene on January 1 for further discussions.
Bharat Biotech to make presentation before expert panel for vaccine approval
By IANS |
Published on
Wed, Dec 30 2020 17:27 IST |
0 Views
Bharat Biotech to make presentation before expert panel for vaccine approval. Image Source: IANS News
New Delhi, Dec 30 : Hyderabad-based Bharat Biotech will make a presentation before the Subject Expert Committee of the Central Drug Standard Control Organisation (CDSCO) on Wednesday evening for approval of its vaccine - Covaxin, government sources told IANS.
Earlier on Wednesday, the Serum Institute of India (SII) s application for emergency use authorisation of its Covid-19 vaccine was also considered by the Subject Expert Committee.
The development came hours after the United Kingdom accepted the recommendation of the Medicines and Healthcare Regulatory Agency (MHRA) to authorise the Oxford University-AstraZeneca s Covid-19 vaccine, Covishield, for emergency approval use.
Indian regulator seeks more time as UK authorises Oxford COVID-19 jab; six things about cheap, easy to store vaccine In India, a decision on emergency usage of the vaccine, which is being manufactured by Pune-based Serum Institute of India, is likely to come next year with the Subject Expert Committee (SEC) on COVID-19 seeking more time today FP Staff December 30, 2020 22:48:25 IST Representational image.
British regulator granted emergency usage authorisation to the easy to store and cheap AstraZeneca/Oxford vaccine on Wednesday.
Though the Indian authorities on Wednesday sought more time to decide on the emergency authorisation of the vaccine, which is manufactured in India as Covishield by Pune-based Serum Institute of India in a tie-up with AstraZeneca, the UK s authorisation has given a shot in the arm to the global fight against coronavirus